Key Points
- Insider Salvatore Privitera sold 8,404 shares for about $546,000 at an average price of $65. The sale was made under a pre-arranged Rule 10b5-1 plan, and he retained 134,341 shares.
- AtriCure reported quarterly earnings of $0.17 per share, beating expectations for a loss of $0.06, and revenue of $154.45 million, above estimates. The company also raised its 2026 revenue guidance to $606 million–$610 million.
- Analyst views remain mixed: the stock has an average “Hold” rating and a $61.80 price target, although several analysts raised their targets after the results.
AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Salvatore Privitera sold 8,404 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $65.00, for a total transaction of $546,260.00. Following the completion of the transaction, the insider directly owned 134,341 shares of the company's stock, valued at $8,732,165. This trade represents a 5.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Salvatore Privitera also recently made the following trade(s):
- On Wednesday, September 23rd, Salvatore Privitera sold 4,519 shares of AtriCure stock. The shares were sold at an average price of $60.00, for a total transaction of $271,140.00.
- On Tuesday, September 8th, Salvatore Privitera sold 3,657 shares of AtriCure stock. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00.
- On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The stock was sold at an average price of $52.50, for a total transaction of $407,557.50.
AtriCure Price Performance
ATRC stock opened at $61.28 on Friday. The stock has a market cap of $3.12 billion, a price-to-earnings ratio of 159.83 and a beta of 1.23. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.33 and a quick ratio of 3.19. The company has a 50 day simple moving average of $56.62 and a 200 day simple moving average of $38.63. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $66.02.
AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.23. AtriCure had a net margin of 2.52% and a return on equity of 4.01%. The firm had revenue of $154.45 million for the quarter, compared to analyst estimates of $151.05 million. Research analysts anticipate that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on ATRC. JPMorgan Chase & Co. increased their price target on AtriCure from $36.00 to $62.00 and gave the company a "neutral" rating in a research note on Wednesday. UBS Group downgraded AtriCure from a "buy" rating to a "sell" rating in a report on Wednesday, October 21st. Freedom Capital lowered AtriCure from a "strong-buy" rating to a "hold" rating in a research report on Friday, October 2nd. Zacks Research cut AtriCure from a "strong-buy" rating to a "hold" rating in a report on Monday, August 24th. Finally, BTIG Research upped their target price on AtriCure from $63.00 to $70.00 and gave the stock a "buy" rating in a report on Wednesday. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $61.80.
Get Our Latest Analysis on AtriCure
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Allworth Financial LP boosted its position in AtriCure by 372.8% during the 2nd quarter. Allworth Financial LP now owns 1,527 shares of the medical device company's stock worth $43,000 after buying an additional 1,204 shares during the period. Rockefeller Capital Management L.P. grew its holdings in AtriCure by 43.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 3,983 shares of the medical device company's stock worth $158,000 after acquiring an additional 1,205 shares during the last quarter. Harbor Investment Advisory LLC acquired a new position in AtriCure in the 2nd quarter valued at approximately $40,000. Sterling Capital Management LLC increased its position in AtriCure by 841.1% in the 3rd quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company's stock valued at $93,000 after acquiring an additional 1,472 shares during the period. Finally, Fulcrum Asset Management LLP acquired a new position in AtriCure in the 3rd quarter valued at approximately $92,000. Institutional investors own 99.11% of the company's stock.
Key Headlines Impacting AtriCure
Here are the key news stories impacting AtriCure this week:
- Positive Sentiment: Third-quarter adjusted earnings were $0.17 per share, ahead of the $0.06-per-share loss analysts expected, while revenue of $154.45 million also topped estimates. AtriCure raised its 2026 revenue guidance to $606 million–$610 million and projected adjusted EBITDA of $91 million–$94 million. AtriCure reports third-quarter results AtriCure outlook and study enrollment
- Positive Sentiment: Several analysts raised price targets following the results. Piper Sandler reiterated Overweight and raised its target to $70; Needham also set a $70 target, while Canaccord raised its target to $67 with a Buy rating. These revisions signal continued confidence in AtriCure’s growth prospects. Analysts raise forecasts Piper Sandler rating
- Neutral Sentiment: JPMorgan raised its target substantially, to $62, but maintained a Neutral rating—suggesting limited upside in its view. JPMorgan rating and target
- Negative Sentiment: A valuation-focused article questioned whether strong results and the higher outlook are already reflected in the stock, which could constrain further gains after its recent run-up. AtriCure valuation discussion
- Negative Sentiment: Insider Salvatore Privitera sold 8,404 shares for about $546,000. The sale was made under a pre-arranged Rule 10b5-1 plan, and he retained 134,341 shares, making the signal less concerning than an unplanned sale. SEC insider filing
About AtriCure
(
Get Free Report)
AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.
The company's product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
